Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders

2021 ◽  
Author(s):  
Andreas A. Argyriou ◽  
Dimos-Dimitrios Mitsikostas ◽  
Elisa Mantovani ◽  
Michail Vikelis ◽  
Stefano Tamburin
Keyword(s):  
Systematic Review ◽  
Chronic Migraine ◽  
Expert Opinion ◽  
Botulinum Neurotoxin ◽  
Primary Headache ◽  
Off Label Use ◽  
Headache Disorders ◽  
Off Label ◽  
Primary Headache Disorders ◽  
Botulinum Neurotoxin Type A

scholarly journals Misperception of Visual Verticality in Patients with Primary Headache Disorders: A Systematic Review with Meta-Analysis

2020 ◽  
Vol 10 (10) ◽  
pp. 664
Author(s):  
Esteban Obrero-Gaitán ◽  
María Manrique-Navarro ◽  
Miguel Ángel Lérida-Ortega ◽  
Daniel Rodríguez-Almagro ◽  
María Catalina Osuna-Pérez ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Primary Headache ◽  
Tension Type Headache ◽  
Healthy Controls ◽  
Headache Disorders ◽  
Primary Headache Disorders ◽  
Visual Vertical ◽  
Newcastle Ottawa Scale ◽  
Type Headache

Migraine and tension-type headache (TTH) are the two most prevalent primary headache disorders (PHDs) that may involve visual and vestibular impairments, neck pain, and postural unsteadiness. The perception of visual verticality (VV) has been studied in patients diagnosed with PHD to assess balance disorders showing varying findings. Our study aimed to assess the VV perception in patients diagnosed with PHD in comparison to healthy controls. A systematic review with meta-analysis was carried out in PubMed MEDLINE, Scopus, WOS, CINAHL, and SciELO. The Cohen standardized mean difference (SMD) was used to estimate the differences between exposed and healthy controls. Seven studies with 816 participants were included. The quality of included studies, according to the Newcastle–Ottawa Scale (NOS), was moderate (mean score of 5.2). Patients diagnosed with PHD showed a moderate misperception of VV as assessed with the subjective visual vertical (SVV) test (SMD = 0.530; 95% CI = 0.225, 0.836; p < 0.001). Specifically, a misperception of the SVV was found in patients with migraine (SMD = 0.369; 95% CI = 0.1, 0.638; p = 0.007) and with TTH (SMD = 1.122; 95% CI = 0.540, 1.704; p < 0.001). This review shows a misperception of VV in patients with migraine and TTH when assessed with the SVV test, being higher in patients with TTH, although the THH sample size was low.

Botulinum neurotoxin for the treatment of migraine and other primary headache disorders

2004 ◽  
Vol 22 (2) ◽  
pp. 167-175 ◽  
Author(s):  
Andrew M Blumenfeld ◽  
David W Dodick ◽  
Stephen D Silberstein
Keyword(s):  
Botulinum Neurotoxin ◽  
Primary Headache ◽  
Headache Disorders ◽  
Primary Headache Disorders

Memantine for the Prevention of Primary Headache Disorders

2014 ◽  
Vol 48 (11) ◽  
pp. 1507-1511 ◽  
Author(s):  
Linda Huang ◽  
Michael Bocek ◽  
Joseph K. Jordan ◽  
Amy Heck Sheehan
Keyword(s):  
Chronic Migraine ◽  
English Language ◽  
Data Extraction ◽  
Primary Headache ◽  
Current Data ◽  
Headache Disorders ◽  
Primary Headache Disorders ◽  
Migraine Headaches ◽  
Study Selection ◽  
Refractory Chronic Migraine

Objective: To describe the current data evaluating the efficacy and safety of memantine for the prevention of primary headache disorders. Data Sources: A literature search using MEDLINE (1966-July 2014) and EMBASE (1973-July 2014) was conducted using the search terms memantine, headache, migraine, glutamate, and NMDA. References of identified articles were reviewed for additional, relevant citations. Study Selection and Data Extraction: All English-language articles dealing with the use of memantine for prevention of primary headache disorders were included. Data Synthesis: Data from several retrospective reports and 2 prospective clinical trials suggest that memantine may be a useful treatment option for the prevention of primary headache disorders. The majority of available literature focuses specifically on chronic migraine prevention in refractory patients who had failed multiple previous prophylactic therapies. In these patients, 10 to 20 mg of memantine daily reduced the frequency and intensity of migraine headaches and was generally well tolerated, with few adverse events. Data regarding the efficacy of memantine for other primary headache disorders such as chronic tension type and cluster headaches are limited. Conclusion: Although further studies evaluating the efficacy of memantine for prevention of primary headache disorders are warranted, memantine may be a reasonable option, used either as monotherapy or adjunctive therapy, in the refractory chronic migraine prophylaxis setting.

Sign in / Sign up

Export Citation Format

Share Document